Market capitalization | $309.88m |
Enterprise Value | $240.22m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 16.88 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-60.99m |
Cash position | $89.08m |
EPS (TTM) EPS | $-14.21 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
6 Analysts have issued a Homology Medicines, Inc. forecast:
6 Analysts have issued a Homology Medicines, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.37 -0.37 |
1,025%
1,025%
|
|
EBITDA | -61 -61 |
47%
47%
|
EBIT (Operating Income) EBIT | -61 -61 |
48%
48%
|
Net Profit | -50 -50 |
62%
62%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.
Head office | United States |
CEO | Jodie Morrison |
Employees | 7 |
Founded | 2015 |
Website | www.q32bio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.